SPX -0.34% VIX 1.42%
HOUSE DEMOCRATS VOTE TO CONDEMN TRUMPS RACIST TWEETS 
STOCKS END LOWER, RETREATING FROM RECORDS AFTER TRUMP STOKES TRADE UNCERTAINTY 
U.S. MANUFACTURING IS IN RECESSION: FED DATA 
TESLA DROPS CHEAPER MODEL S, MODEL X OPTIONS 
SHORT COVERING PLAYS PART AS BLUE APRON ROCKETS 50% ON BEYOND MEAT NEWS 
HBOS GAME OF THRONES GETS RECORD-BREAKING 32 EMMY NOMINATIONS 
TRUMP AGREES WITH ALLY AND FACEBOOK BOARD MEMBER THAT GOOGLE SHOULD BE PROBED 
THINK YOUR INCOME LEVEL IS TOO HIGH FOR A ROTH IRA? THINK AGAIN 
GOLDMAN SACHS SHARES HELP DOW MAINTAIN INTRADAY GAIN 
DOW TAPS ALL-TIME INTRADAY HIGH AS INVESTORS WEIGH BIG-BANK EARNINGS 
Wed, Jul 17 4:32am


Incyte Corp [INCY]
$79.88 1.51 (1.86%)

INCY Profile

Sector Health Care
Industry Biotech & Pharma
Market Cap 17.18 Billion
INCY Description

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant, which Eli Lilly licenses, and oncology drug Iclusig for chronic myeloid leukemia. Incyte's pipeline includes a broad array of oncology and autoimmune programs, including next-generation JAK inhibitor itacitinib.


Visit Website

INCY Earnings

EPS 0.48 P/E Ratio 145.02
Previous Earnings Tue, Apr 30, 2019
Latest Earnings Tue, Jul 30, 2019 (In 13 days)

INCY Dividend

Yield --
Ex-Date --
Pay Date --
History --

INCY Charts

$57.00
52 Week Range
$88.85
Dec 24, 2018
Jun 21, 2019



Symbol Price Day % YTD %
INCY $79.88 -1.86% 25.68%

Symbol Surfing

How can we make Symbol Surfing better?

info@symbolsurfing.com

Information is provided "as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.



©2019 Symbol Surfing All Rights Reserved.

Cookies Policy | Terms Of Service | Privacy Policy